New Guardant Health Director Gadde Gets Options and RSUs Worth Over Half Million

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Guardant Health director Vijaya Gadde received new equity compensation grants on June 18, 2025, consisting of:

Stock options to purchase 6,833 shares of common stock at an exercise price of $50.57 per share, expiring June 18, 2035
4,203 Restricted Stock Units (RSUs) with no exercise price

Both the stock options and RSUs will fully vest on the earlier of: (1) the one-year anniversary of the grant date (June 18, 2025) or (2) the date of the next annual stockholders meeting. This equity compensation package appears to be part of standard director compensation. The Form 4 was filed by John G. Saia as attorney-in-fact for Vijaya Gadde on June 20, 2025.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Gadde Vijaya

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	6,833	$0.00	--
Grant/Award	Restricted Stock Units	4,203	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 6,833 shares (Direct); Restricted Stock Units — 4,203 shares (Direct)

Footnotes (1)

The stock option vests in full on the one-year anniversary of the grant date, June 18, 2025 or the date of the next year annual stockholders meeting, whichever is earlier. The restricted stock units vest in full on the one-year anniversary of the grant date, June 18, 2025 or the date of the next year annual stockholders meeting, whichever is earlier. Not applicable for Restricted Stock Units.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 06/20/2025 - 05:28 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gadde Vijaya

(Last)

(First)

(Middle)

3100 HANOVER STREET

(Street)

PALO ALTO

94304

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$50.57	06/18/2025		A		6,833		⁽¹⁾	06/18/2035	Common Stock	6,833	$0	6,833	D
Restricted Stock Units	$0	06/18/2025		A		4,203		⁽²⁾	⁽³⁾	Common Stock	4,203	$0	4,203	D

Explanation of Responses:

1. The stock option vests in full on the one-year anniversary of the grant date, June 18, 2025 or the date of the next year annual stockholders meeting, whichever is earlier.

2. The restricted stock units vest in full on the one-year anniversary of the grant date, June 18, 2025 or the date of the next year annual stockholders meeting, whichever is earlier.

3. Not applicable for Restricted Stock Units.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Vijaya Gadde	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What stock options did Guardant Health (GH) director Vijaya Gadde receive on June 18, 2025?

Director Vijaya Gadde received 6,833 stock options with an exercise price of $50.57 per share. These options will vest in full on June 18, 2026 (one-year anniversary) or the date of the next annual stockholders meeting, whichever occurs earlier. The options expire on June 18, 2035.

How many Restricted Stock Units (RSUs) were granted to GH director Vijaya Gadde in June 2025?

Vijaya Gadde was granted 4,203 Restricted Stock Units (RSUs) on June 18, 2025. These RSUs will vest in full on the one-year anniversary of the grant date (June 18, 2026) or the date of the next annual stockholders meeting, whichever occurs earlier.

What is the vesting schedule for GH director Vijaya Gadde's June 2025 equity grants?

Both the stock options and RSUs granted to Vijaya Gadde follow the same vesting schedule: they vest 100% on the one-year anniversary of the grant date (June 18, 2026) or the date of the next annual stockholders meeting, whichever occurs earlier.

What is the total value of equity compensation granted to Guardant Health director Vijaya Gadde in June 2025?

The Form 4 shows that Vijaya Gadde received two equity grants: 6,833 stock options with a strike price of $50.57 and 4,203 Restricted Stock Units with a $0 exercise price. Both were granted on June 18, 2025, as part of director compensation. The actual value will depend on GH's stock price performance.